PNT2258: Additional Phase II data

Data from 13 patients in an open-label, U.S. Phase II trial showed that 120 mg/m 2 IV PNT2258 on days 1-5 of a 21 day cycle led to a clinical benefit in 11 patients, with ongoing progression-free survival (PFS) “extending to 18 months and beyond.” In 4 patients with diffuse large Beta cell lymphoma (DLBCL), PNT2258 led to 3 complete responses and 1 partial response. In 5 patients with follicular lymphoma, there was 1 complete response, 1 partial response and 3 cases of stable disease. In 2 patients with chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL), there was 1 case of stable disease. In 2 patients with mantle cell lymphoma (MCL), there was 1 case of stable disease. PNT2258 was well tolerated. Data were presented at the American Society of Hematology meeting in San Francisco. Marina and ProNAi previously reported data interim data (see BioCentury, Dec. 23, 2013). ...